|Day Low/High||0.61 / 0.67|
|52 Wk Low/High||0.50 / 3.48|
The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.
Cardium Therapeutics (NYSE MKT: CXM) today announced that Christopher J.
Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.
Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.
Several stocks trading near $5 were poised to move on above-average volume during Wednesday's session.
Risky late-game call puts Poniard in a deep financial hole.
Is it the drug or the gel that worked best in a phase II study?
The fall in Cardium shares might be related, at least partially, to what looks like so-so results from a phase IIb study announced on Oct. 14.
Cardium Therapeutics fell sharply on heavy volume after it announced a $6 million registered direct offering.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.